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A B S T R A C T
Since Dec. 2019 the new coronavirus (SARS-CoV-2) has infected millions and claimed life of several hundred
thousand worldwide. However, so far no approved vaccine or drug therapy is available for treatment of virus
infection. Convalescent plasma has been considered a potential modality for COVID-19 infection. One hundred
eighty-nine COVID-19 positive patients including 115 patients in plasma therapy group and 74 patients in
control group, registered in the hospitals with confirmed COVID-19 infection, entered this multi-center clinical
study. Comparison of outcomes including all-cause mortality, total hospitalization days and patients’ need for
intubation between the two patient groups shows that total of 98 (98.2 %) of patients who received convalescent
plasma were discharged from hospital which is substantially higher compared to 56 (78.7 %) patients in control
group. Length of hospitalization days was significantly lower (9.54 days) in convalescent plasma group com-
pared with that of control group (12.88 days). Only 8 patients (7%) in convalescent plasma group required
intubation while that was 20 % in control group. This clinical study provides strong evidence to support the
efficacy of convalescent plasma therapy in COVID-19 patients and recommends this treatment for management
of these patients. Clinical efficacy, immediate availability and potential cost effectiveness could be considered as
main advantages of convalescent plasma therapy.
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1. Introduction
Shortly after WHO announcement of first signs of SARS-CoV-2, the
virus that causes COVID-19 epidemic in the world on Dec. 31, 2019, the
epidemic of new coronavirus quickly changed all aspects of the people’s
lives around the world. Countries’ health care system soon became
overwhelmed with exponentially growing number of patients referring
to health care centers with severe acute respiratory syndrome (ARDS)
symptoms. The mortality is high and considerable percentage of the
patients contracted COVID-19, requires ICU admission and rapidly de-
velops ARDS. There is no vaccine or specific anti-viral drug therapy yet
to treat patients. Iran reported its first two cases of COVID-19 on Feb.
19, 2020 in the city of Qom and the disease rapidly spread to other
cities and shortly to the whole country [1]. By the 4 July 2020, more
than 237,000 cases tested positive and nearly 11,400 deaths were re-
ported in Iran.
One of the hopeful treatment that has emerged is convalescent
plasma therapy which is plasma that is collected from an infected in-
dividual by COVID-19 is then transfused into infected patients.
Convalescent plasma has been used for SARS, 2009 influenza A (H1N1)
pandemic, avian influenza A (H5N1), MERS, Ebola, and other viral
infections to improve the survival rate of patients. Most of the published
papers reported a significantly better patient’s outcome with con-
valescent plasma [2–6].
A key advantage to convalescent plasma is that this treatment is
provided by people who have been infected previously and is available
immediately. It is also cost effective for resource limited medical cen-
ters. If it is infused at proper time, it may prevent patient getting into
severe stage of the disease and reduce possibility of hospitalization in
ICU.
Deploying passive antibody therapies against the rapidly increasing
number of COVID-19 cases provides an opportunity to study the effi-
cacy of this treatment against this new viral agent [7–12]. One possible
explanation for the efficacy of convalescent plasma therapy is that the
antibodies from convalescent plasma might suppress viraemia. Based
on current data, viraemia peaks in the first week of infection in most
viral illnesses. The patient usually develops a primary immune response
by days 10–14. Therefore, probably, administration of convalescent
plasma at the early stage of disease would create more benefit to the
patients [13,14].
There are several published papers reporting use of convalescent
plasma in COVID-19 patients [15]. In a case series study, 5 critically ill
COVID-19 patients were treated with convalescent plasma. As assessed
by computerized tomography (CT) Scan, viral load declined within days
of treatment and the clinical conditions improved. Four patients who
had been receiving mechanical ventilation and Extracorporeal mem-
brane oxygenation (ECMO), no longer required respiratory support by 9
days after plasma transfusion [16].
In another case series study, 10 severe COVID-19 patients were re-
ceived one dose of 200 mL of convalescent plasma with the neutralizing
antibody titers above 1:640 in addition to maximal supportive care and
antiviral agents. After convalescent plasma therapy, the clinical symp-
toms were significantly improved along with increase of oxyhe-
moglobin saturation within 3 days [17].
A case series of two cases of COVID-19 treated with convalescent
plasma infusion in Korea described that both patients presented severe
pneumonia with ARDS and showed a favorable outcome after the use of
convalescent plasma [18]
Despite low number of reported cases with COVID-19 convalescent
plasma therapy, well known national regulatory agencies such as FDA
on April 13, 2020 authorized use of convalescent plasma as a poten-
tially effective treatment of the patients [19]. EU also issued its pro-
gram for collection and use of convalescent plasma in COVID-19 pan-
demic as an immediately available experimental therapy with low risk,
which should be considered as an urgent priority [20].
However, convalescent plasma is now being used in very large
number of patients [21].
One obstacle in plasma therapy is providing convalescent plasma in
large number to enable medical centers to use them routinely.
Therefore, scalability to treat large numbers of patients may become an
issue. In order to tackle logistical challenge of providing convalescent
plasma it should be needed to encourage and regulate blood and plasma
centers to collect COVID-19 convalescent plasma [22]. A stockpile of
frozen convalescent plasma would be a precious asset in fight against
COVID-19.
However, it was important to perform well controlled clinical trials
to confirm efficacy of this modality to provide evidence for evidence-
based decision making. Amidst the shortage of robust evidence re-
garding the use of this treatment in COVID-19 patients, the present
study aims to explore the efficacy of administrating convalescent
plasma to COVID-19 patients in a nonrandomized multi-center clinical
trial. To the best of our knowledge, this is the only reported case control
clinical study of use of convalescent plasma in COVID-19 patients
2. Materials and methods
Following approval of the ethical committee, this clinical study re-
gistered in Iran National Registry for Clinical Trails
(IRCT20200325046860N1). The study was conducted between March
to April 2020. Patients were recruited from confirmed COVID-19 in-
fected patients. The presence of COVID-19 infection in patients was
confirmed by quantitative real time polymerase chain reaction (qRT-
PCR) on their admission to the hospital.
Demographic information of the enrolled patients is presented in
Table 1. CT scan scoring was performed using a lung CT scan scoring
system to evaluate the patient’s lung involvement. CT scan was assessed
for ground glass opacity, crazy paving, or consolidation in both lung
fields. Each of the five lung lobes was scored from 0 to 5 based on the
percentage of lobar involvement as follows: no involvement [0], 75 %
[5]. Total CT scan score was calculated by adding five lobar scores and
ranged from 0 (no involvement) to 25 (maximum involvement) [23].
2.1. Hospitals contribution
Enrolment of the patients (case and control) for this clinical trial
were done in Baqiyatallah Hospital, MasihDaneshvari Hospital,
Labbafinejad and RasoolAkram (Tehran), Beheshti Hospital (Qom),
Qarazi Hospital (Isfahan) and Sadouqi Hospital (Yazd). However, most
of the patients for this study have recruited from Baqiyatallah Hospital.
This hospital from February 19, 2020 to April 15, 2020, received
12,870 patients of which 2,968 were hospitalized with COVID-19 di-
agnosis. The majority of cases were in the age group of 50–60 years of
old. The male-to-female ratio was 1.93:1. A total of 239 deaths occurred
among all cases for an overall Case Fatality Ratio (CFR) of 1.85 % based
Table 1
Demographic and basic clinical factors of patient groups on admission.
Variables Patient groups p-value
Plasma (n=115) Control (n=74)
Age, year Mean ± SD 54.41 ± 13.71 56.83 ± 14.98 0.250
Range 23–93 19–90
Gender, n (%) Male 67 (58.3%) 37 (50.0%) 0.265
Female 48 (41.7%) 37 (50.0%)
Hypertension, n (%) No 58 (72.5%) 31 (62.0%) 0.210
Yes 22 (27.5%) 19 (38.0%)
Diabetes, n (%) No 53 (66.3%) 34 (68.0%) 0.837
Yes 27 (33.8%) 16 (32.0%)
On admission chest
CT scan score
Mean ± SD 13.81 ± 4.87 13.36 ± 5.67 0.719
Range 4–23 2–23
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on the total number of patients and 8.06 % among hospitalized patients
[24].
2.2. Convalescent plasma donors
Convalescent plasma donors were selected from clinically and la-
boratory-confirmed recovered patients of COVID-19 who were between
18–60 years old. To prevent transfusion related acute lung injury
(TRALI) female donors with a history of pregnancy were excluded.
Selected donors had negative qRT-PCR for COVID-19 and other stan-
dard virology tests at the time of donation while their test results had
been previously positive by qRT-PCR for COVID-19. Additionally, all
donors should have no remaining symptoms of COVID-19 infection at
least 14 days prior to donation. They were interviewed and examined
by qualified physician and were asked to fill in related plasma donation
and consent forms. Eligible donors were tested by the semi-quantitative
enzyme-linked immunosorbent assay (ELISA) antibody identification
test for COVID-19. Volume of donated plasmas was 500cc.
Donated plasma was tested by the semi-quantitative ELISA and
Rapid Strip Test (IgG 98 % Pos, IgM 75 % Pos) antibody identification
test for COVID-19. Based on laboratory testing, donated plasmas con-
tained antibody titer cut off index higher than 1.1. Sampling from do-
nated plasma was done in order to perform routine screening tests for
transfusion transmitted infections (HIV, HBV, HCV, RPR). Donated
plasma was stored in freezers till the release of screening tests’ results.
After meeting the eligibility criteria for transfusion, donated plasma
was sent to hospital blood banks.
2.3. Convalescent plasma recipient
Recipients who met the inclusion criteria were selected by re-
sponsible physicians. Following signing the consent forms by recipient
or authorized family members, the request for releasing convalescent
plasma was sent to the hospital blood bank. Plasma transfusion to the
recipient was performed according to standards for normal plasma in-
cluding conformity of blood groups. The first 500 cc (one unit) plasma
was infused within four hours and if the patient did not show any im-
provement after 24 h, based on the decision of responsible physician,
another unit of plasma was administrated. All clinical and para clinical
data was recorded and transferred to the researcher. Patients’ follow up
during hospitalization was performed by a monitoring chart every 12 h.
2.4. Patients
Criteria for inclusion and exclusion of the patients for this clinical
study were as followings.
Inclusion Criteria - Patients who met all following criteria received
convalescent plasma:
1 Age ≥ 18 years
2 Confirmed COVID-19 infection through laboratory (RT-qPCR) and/
or lung involvement confirmed with chest imaging (CT scan)
3 Presence of some or all of disease clinical symptoms such as short-
ness of breath (dyspnea), respiratory frequency ≥ 20/min, fever
and cough
4 Hospitalized with a blood oxygen saturation (SPO2) ≤93 % at rest
on room air
5 ≤7 days since illness onset
6 Willingness to participate in the trail and sign the consent form
Exclusion Criteria - Patients with either of following criteria ex-
cluded from the trail:
1 Intubated patients or patients on mechanical ventilation.
2 Severe liver or kidney disease
3 Septic Shock
4 Physician decision that convalescent plasma therapy is not in pa-
tients' best interest
5 Patients with improving clinical conditions who meet hospital dis-
charge criteria (defined as clinical recovery, i.e. return of body
temperature, respiratory rate, oxygen saturation to normal and
cough relief).
6 Known hypersensitivity to plasma
2.5. Outcome measures and definitions
The primary outcomes were the patient survival and length of
hospital stay. Secondary outcomes included patients’ needs for in-
tubation, improvements in clinical symptoms such as tachypnea and
para clinical measured of the patients and frequency of adverse effects
resulting from plasma transfusion.
2.6. Statistical reporting
Categorical variables were expressed as counts (percentage), and
continuous variable as Range and mean ± standard deviation (SD). The
comparison demographic and clinical characteristics between two
groups was assessed by t-test or Mann Whitney test for continuous
variable and Chi-Square or Fisher's Exact test for categorical variables.
All analyses were performed by using IBM® SPSS® 23.0. The P value less
than 0.05 was considered significance level.
3. Results
3.1. Baseline features
Totally 189 patients (115 convalescent plasma treatment group and
74 control group) registered in this clinical study. Treatment and con-
trol groups, except for their number of patients, were matched based on
gender, age and presence of two main comorbidities including hy-
pertension and diabetes of mellitus (Table1). Their chest CT scan scores
was also statistically matched indicating that both patient groups had
similar clinical conditions on their entrance into the study. All patients
in case and control groups received similar routine antiviral therapy
including Lopinavir/Ritonavir, Hydroxychloroquine and an anti-in-
flammatory agent.
3.2. Safety, Clinical and para Clinical measures of the patients
Although there are some concerns regarding possibility of antibody
dependent enhancement (ADE) in convalescent plasma therapy [25],
except in one case (transient mild fever and chill following infusion of
the plasma) no adverse effect was observed resulting from convalescent
plasma transfusion during the study. Clinical parameters and laboratory
measures of patient groups are shown in Tables 2 and no significant
difference was found between treatment and control groups on their
admission into the hospital. Table 3 shows comparison of outcomes
including all-cause mortality, total hospitalization days and needs for
intubation between the two patients’ groups. Total of 98 (98.2 %) of
patients who received convalescent plasma were discharged from hos-
pital which is substantially higher compared to 56 (78.7 %) patients in
control group. Length of hospital stay was significantly lower (9.54
days) in convalescent plasma group compared with that of control
group (12.88 days). Only 8 patients (7%) in convalescent plasma group
required intubation while this value was 20 % in control group.
4. Discussion
Based on results of this multicenter clinical study administration of
convalescent plasms to COVID-19 infected patients resulted in
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significant improvements of their clinical outcomes including all-cause
mortality, hospital length of stay and needs to mechanical ventilation.
Similar to the most viral illnesses the primary immune response de-
velops by days 10–14, which is followed by virus clearance. Therefore,
transfusion of convalescent plasma at the early stage of disease theo-
retically should be more effective. Early administration of convalescent
plasma in COVID-19 patients is a critical measure for its clinical effi-
cacy. Therefore, all patients in treatment group received convalescent
plasma in less than 3 days of their hospital admission. However,
availability of blood group match plasma was a determinant factor to
define time of convalescent plasma administration.
Convalescent plasma substantially reduced all-cause mortality in
treatment group compared with control group (14.8 % vs 24.3 %).
However, this was not statistically different. Smaller number of patients
in control group (74) compared to plasma group (115) might contribute
to this phenomenon.
Convalescent plasma therapy significantly reduced patients’ hospi-
talization period from 12.88 days to 9.54 days (Table 3). This obviously
increases availability of hospital beds in this virus pandemic. This effect
also will considerably reduce treatment costs of COVID-19 infected
patients. It should be mentioned that for this comparison we consider
date of admission as start day of hospitalization for both treatment and
control groups. However, based on calculation of length of hospital stay
since administration of convalescent plasma, reduction in length of
hospitalization will be more prominent and hospitalization period of
treatment group will further reduce to 6.25 days (Table 3). Ad-
ditionally, 28.1 % of patients who received convalescent plasma dis-
charged from hospital in less than 5 days after transfusion compared to
8.9 % in control group.
Convalescent plasma also significantly reduced needs to mechanical
ventilation in treatment group compared to control group (7% vs 20.3
%). Since it was previously reported that patients who require intuba-
tion have poor prognosis [26] this reduction likely contributed to better
final outcomes in convalescent plasma group.
5. Study limitation
Due to clinical features of the patients it was not possible for the
investigators to design the study as a randomized clinical trial.
Therefore, the main limitation of this study was related to assigning
patients into control group. Due to ethical consideration, responsible
physicians were reluctant to deprive COVID-19 patients from con-
valescent plasma therapy. Therefore, patients in control group were
mainly comprises of patients with mild clinical presentation who did
not have blood group convalescent plasma match on their hospital
admission or in the next 3 days. That is why number of patients in
control group is substantially smaller than treatment group. The other
limitation is the use of other treatment regimens including antiviral
medications along with convalescent plasma transfusion, which was
inevitable.
In this study convalescent plasma administered in less than 3 days of
hospital admission, it is unclear whether this timing is optimal or if
earlier administration might have been associated with different clin-
ical outcomes. Although we have administrated 500 mL of convalescent
plasma, optimal volume of plasma should also be determined.
6. Conclusion
The nonrandomized clinical trial presented here demonstrates the
clinical efficacy of convalescent plasma in COVID-19 infected patients
and indicates that convalescent plasma treatment should be considered
as a safe and effective therapy for COVID-19 patients. Convalescent
plasma therapy substantially improved patients’ survival, significantly
reduced hospitalization period and needs for intubation in COVID-19
patients in comparison with control group. Despite some limitations,
this clinical study provides strong evidence to support the efficacy of
convalescent plasma therapy in COVID-19 patients and therefore this
therapy is recommended for better management of these patients.
Table 2
Clinical parameters and laboratory measures of patient groups on admission.





Vital signs SpO2 (%) 85.95 ± 6.42 84.00 ± 8.57 0.100
sBP 124.68 ± 16.70 125.86 ± 17.16 0.872
dBP 75.56 ± 10.71 79.74 ± 13.21 0.088
Laboratory
Parameter
WBC 7.53 ± 5.07 7.89 ± 4.74 0.464
Lymph 1346 ± 2822 1189 ± 722 0.542
Hb 13.77 ± 1.93 14.49 ± 8.82 0.709
PLT 196.50 ± 77.60 207.82 ± 86.97 0.289
CRP 26.27 ± 28.66 33.65 ± 29.90 0.116
LDH 676.09 ± 289.77 654.33 ± 317.68 0.520
Albumin 3.58 ± 0.54 3.49 ± 0.54 0.397
Cr 1.17 ± 0.89 1.37 ± 1.48 0.205
BUN 20.26 ± 13.72 20.56 ± 15.93 0.957
Ferritin 472.11 ± 426.29 454.95 ± 318.98 0.461
CPK 264.44 ± 232.98 311.33 ± 389.74 0.241
ESR 49.25 ± 29.17 58.39 ± 30.15 0.104
Table 3
Comparison of primary and secondary outcomes between the two groups.
Outcome Patient groups p-value
Plasma (n = 115) Control (n = 74)
All-cause mortality Died, (n; %) 17 (14.8 %) 18 (24.3 %) 0.09
Alive, (n; %) 98 (85.2 %) 56 (75.7 %)
Length of stay, day1 Mean ± SD 9.54 ± 5.07 12.88 ± 7.19 0.002
Range 2−24 2−32
Length of stay, day2 Mean ± SD 6.25 ± 4.33 12.88 ± 7.19 0.000
Range 0−20 2−32
Patients discharged from hospital ≤5 days post admission n (%) 27 (28.1 %) 5 (8.9 %) 0.010
Intubation No, (n; %) 107 (93 %) 59 (79.7 %) 0.006
Yes, (n; %) 8 (7.0 %) 15 (20.3 %)
1Total hospital stay based on 1st day of hospital admission.
2Total hospital stay based on 1st day of convalescent plasma transfusion.
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